SCHEMBL2654547

SCHEMBL2654547

CCOC(=O)c1ccc2c(c1)ncn2-c1cccc(COCc2ccncn2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.46
FGFR1 P11362 3/20 0.46
KMT2A Q03164 2/20 0.46
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.41
NAMPT P43490 1/20 0.40
TP53 P04637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651812 0.90 FGFR1 (0.50) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652993 0.87 GABRA1 (0.54) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2651677 0.83 HPGD (0.47) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652175 0.83 HPGD (0.46) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652427 0.83 HPGD (0.46) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652775 0.83 HPGD (0.46) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652387 0.82 KIT (0.39) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652953 0.82 FGFR1 (0.39) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652990 0.81 FGFR1 (0.57) HPGDFGFR1KMT2AGABRA1GABRG2
SCHEMBL2652605 0.80 FGFR1 (0.52) HPGDFGFR1KMT2AGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP claimed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 HPGD 1855/4885FGFR1 4324/4885KMT2A 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.